title: [Secondary prevention of myocardial infarction in the Ile de France].
abstract: This enquiry was carried out to evaluate the measures of secondary prevention at 6 months and over of myocardial infarction in the ile de France region with respect to the recommendations of scientific societies and results of large scale therapeutic trials. A questionnaire was completed for the 1,215 patients selected from data obtained from the hospital discharge summary, interrogation and examination of the patient, and a telephone conversation with the attending physician. The data covered cardiovascular risk factors, the main clinical parameters, the results of biological tests and investigations carried out for risk stratification, plus different elements of therapeutic management. Compared with previous studies of the same type, this enquiry showed a favourable tendency towards the prescription of antithrombotic drugs and betablockers (98.3% and 82.4% of patients, respectively), and to patients with reputedly normal blood pressure values (84.7%). A positive result concerning the reduction in the number of smokers (17.4%) and the increase in lipid lowering prescriptions should be tempered by the fact that advice about stopping smoking was rarely given and that the quantitative target of LDL cholesterol was often ignored. Finally, the prescriptions of ACE inhibitors, physical exercise and cardiac rehabilitation remained well below the recommendations or recent scientific data.
authors: Service médical de l'assurance maladie, Echelon local du Val-de-Marne, 1-9, avenue du Général de Gaulle, 94031 Créteil.
authors: E
authors: E
authors: Bérigaud
authors: L
authors: L
authors: Silvera
authors: D
authors: D
authors: Du Bron
authors: E
authors: E
authors: Dupont-Zacot
authors: C
authors: C
authors: Chabry
authors: B
authors: B
authors: Trutt
authors: B
authors: B
authors: Blanchon
authors: M
authors: M
authors: Parmentier
authors: P
authors: P
authors: Hecquard
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001794:Blood Pressure; D005260:Female; D005343:Fibrinolytic Agents / Q000627:therapeutic use*; D005500:Follow-Up Studies; D005602:France; D006801:Humans; D006937:Hypercholesterolemia / Q000150:complications; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000473:pathology / Q000517:prevention & control*; D011379:Prognosis; D012008:Recurrence; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects
chemical_list: D000319:Adrenergic beta-Antagonists; D005343:Fibrinolytic Agents